CRC Research Update — September 13, 2026
Today's colorectal cancer research highlights
msi-h
A collection of 92 issues
Secondary actionable fusions in MLH1-deficient MSI-H tumors may impact pembrolizumab outcomes
Skip to content
The CRC Digest
Secondary actionable fusions in MLH1-deficient MSI-H tumors may impact pembrolizumab outcomes
A molecular subanalysis of the GAstrointestinal INestable cohort evaluated secondary fusions in MLH1-deficient dMMR/MSI-H gastrointestinal tumors treated with pembrolizumab, finding that these fusions may be enriched in MLH1-deficient colorectal cancer with mitogen-activated
CRC Research Update — September 12, 2026
Today's colorectal cancer research highlights
39-year-old proband with Lynch syndrome shows discordant tumor testing
Skip to content
The CRC Digest
◇ RESEARCH
39-year-old proband with Lynch syndrome shows discordant tumor testing
A 39-year-old man with colorectal cancer and family history fulfilling Amsterdam criteria carried the germline MLH1 c.931A>G variant, with tumors showing MSI-H status despite retained MMR protein expression. (Clinical Case Reports)
Lynch syndrome family shows MSI-H tumors despite preserved MMR protein staining
Skip to content
The CRC Digest
◇ RESEARCH
Lynch syndrome family shows MSI-H tumors despite preserved MMR protein staining
A family carrying germline MLH1 c.931A>G presented with colorectal tumors showing retained mismatch repair protein expression by immunohistochemistry but microsatellite instability-high status on sequencing, highlighting that preserved staining does
CRC Research Update — September 11, 2026
Today's colorectal cancer research highlights
CRC Research Update — September 09, 2026
Today's colorectal cancer research highlights
Cytokines May Modulate Checkpoint Inhibitor Response in MSI-H CRC
Skip to content
The CRC Digest
◇ RESEARCH
Cytokines May Modulate Checkpoint Inhibitor Response in MSI-H CRC
A review highlights how cytokines can critically modulate immune checkpoint inhibitor effectiveness in mismatch repair-deficient/microsatellite instability-high colorectal cancer by influencing checkpoint expression and shaping the tumor microenvironment. (Critical Reviews in Oncology/Hematology)
This
Cost-Effectiveness Analysis Compares Immunotherapy Options for MSI-H/dMMR mCRC
Skip to content
The CRC Digest
▸ TREATMENT
Cost-Effectiveness Analysis Compares Immunotherapy Options for MSI-H/dMMR mCRC
A U.S. healthcare payer analysis evaluated nivolumab plus ipilimumab versus pembrolizumab and chemotherapy as first-line treatment for the 4-5% of metastatic colorectal cancers that are microsatellite instability-high or mismatch repair deficient. (Advances in
CRC Research Update — September 07, 2026
Today's colorectal cancer research highlights